Published in J Urol on March 14, 2009
Evaluation of renal masses with contrast-enhanced ultrasound: initial experience. AJR Am J Roentgenol (2011) 1.56
Tumour location as a predictor of benign disease in the management of renal masses. Can Urol Assoc J (2010) 1.49
Active surveillance for small renal masses. Rev Urol (2012) 0.95
Imaging renal cell carcinoma with ultrasonography, CT and MRI. Nat Rev Urol (2010) 0.94
Heterogeneity and renal mass biopsy: a review of its role and reliability. Cancer Biol Med (2014) 0.93
Partial nephrectomy for selected renal cortical tumours of ≥ 7 cm. BJU Int (2010) 0.91
Solid renal masses: what the numbers tell us. AJR Am J Roentgenol (2014) 0.90
Imaging findings of common benign renal tumors in the era of small renal masses: differential diagnosis from small renal cell carcinoma: current status and future perspectives. Korean J Radiol (2015) 0.89
Tumor doubling time of renal cell carcinoma measured by CT. Indian J Urol (2014) 0.88
Active surveillance of small renal masses. Nat Rev Urol (2013) 0.86
3D cone-beam CT guidance, a novel technique in renal biopsy--results in 41 patients with suspected renal masses. Eur Radiol (2012) 0.83
The role of pathology in small renal mass laparoscopic cryoablation. Adv Urol (2012) 0.81
Is tumor size a reliable predictor of histopathological characteristics of renal cell carcinoma? Urol Ann (2012) 0.81
Assessment of intratumoral micromorphology for patients with clear cell renal cell carcinoma using susceptibility-weighted imaging. PLoS One (2013) 0.80
Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics (2012) 0.80
Sarcoidosis manifesting as a pseudotumorous renal mass. J Radiol Case Rep (2013) 0.80
Discrepancy between radiological and pathological size of renal masses. BMC Urol (2011) 0.79
Preoperative predictors of malignancy and unfavorable pathology for clinical T1a tumors treated with partial nephrectomy: a multi-institutional analysis. Urol Oncol (2014) 0.79
Multiparametric magnetic resonance imaging for the differentiation of low and high grade clear cell renal carcinoma. Eur Radiol (2014) 0.78
Multiphasic contrast-enhanced MRI: single-slice versus volumetric quantification of tumor enhancement for the assessment of renal clear-cell carcinoma fuhrman grade. J Magn Reson Imaging (2012) 0.78
18-F fluorodeoxyglucose uptake in positron emission tomography as a pathological grade predictor for renal clear cell carcinomas. Eur Radiol (2015) 0.77
Neutrophil-lymphocyte ratio in small renal masses. ISRN Urol (2014) 0.77
Relationship between computed tomography morphology and prognosis of patients with stage I non-small cell lung cancer. Onco Targets Ther (2017) 0.75
Usefulness of the ice-cream cone pattern in computed tomography for prediction of angiomyolipoma in patients with a small renal mass. Korean J Urol (2013) 0.75
Aquaporin-1 protein levels elevated in fresh urine of renal cell carcinoma patients: potential use for screening and classification of incidental renal lesions. Dis Markers (2014) 0.75
Current Status of Nephron-Sparing Surgery (NSS) in the Management of Renal Tumours. Indian J Surg Oncol (2017) 0.75
Microscopic papillary tumor in a renal needle biopsy specimen for IgA nephropathy. NDT Plus (2011) 0.75
Pre-treatment neutrophil-to-lymphocyte ratio predicts tumor pathology in newly diagnosed renal tumors. World J Urol (2016) 0.75
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol (2006) 8.61
Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol (2008) 5.30
External validation is necessary in prediction research: a clinical example. J Clin Epidemiol (2003) 3.49
Solid renal tumors: an analysis of pathological features related to tumor size. J Urol (2003) 3.48
Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol (2000) 3.26
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol (2007) 2.83
Comparative analysis of laparoscopic versus open partial nephrectomy for renal tumors in 200 patients. J Urol (2003) 2.77
Diagnostic accuracy of computed tomography-guided percutaneous biopsy of renal masses. Eur Urol (2007) 2.39
5-Year outcomes of laparoscopic partial nephrectomy. J Urol (2007) 2.20
Complications of contemporary open nephron sparing surgery: a single institution experience. J Urol (2005) 2.10
Percutaneous and laparoscopic cryoablation of small renal masses. J Urol (2008) 1.80
Contemporary imaging of patients with a renal mass: does size on computed tomography equal pathological size? BJU Int (2008) 1.79
Active surveillance of renal masses in elderly patients. J Urol (2008) 1.57
Partial nephrectomy for patients with a solitary kidney: the Memorial Sloan-Kettering experience. BJU Int (2004) 1.15
Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults. J Urol (1999) 1.04
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol (2002) 9.05
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol (2006) 8.61
Guideline for management of the clinical T1 renal mass. J Urol (2009) 8.26
Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes? J Urol (2008) 5.70
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol (2004) 4.68
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol (2009) 4.27
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol (2012) 3.20
Assessing the impact of ischaemia time during partial nephrectomy. Eur Urol (2009) 3.18
Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol (2012) 3.03
The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol (2010) 3.02
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med (2012) 2.95
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol (2007) 2.83
Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer (2005) 2.78
Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. J Urol (2013) 2.76
Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology (2005) 2.71
Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol (2006) 2.70
Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol (2003) 2.67
Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology (2002) 2.63
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer (2008) 2.53
Adult spermatic cord sarcomas: management and results. Ann Surg Oncol (2003) 2.52
Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA (2012) 2.49
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res (2009) 2.42
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol (2002) 2.39
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37
Comparison of open and minimally invasive partial nephrectomy for renal tumors 4-7 centimeters. Eur Urol (2011) 2.36
Complications after radical and partial nephrectomy as a function of age. J Urol (2010) 2.36
Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol (2009) 2.32
Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol (2008) 2.30
A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol (2005) 2.30
Prognostic nomogram for renal insufficiency after radical or partial nephrectomy. J Urol (2006) 2.30
Adult genitourinary sarcoma: the 25-year Memorial Sloan-Kettering experience. J Urol (2006) 2.30
Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? Eur Urol (2010) 2.27
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res (2013) 2.26
Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology (2007) 2.23
Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology (2013) 2.21
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
Mini-flank supra-11th rib incision for open partial or radical nephrectomy. BJU Int (2006) 2.19
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A (2007) 2.11
Complications of radical and partial nephrectomy in a large contemporary cohort. J Urol (2004) 2.09
Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors. J Urol (2009) 2.05
Management of low grade papillary bladder tumors. J Urol (2007) 2.04
Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov (2011) 2.02
Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm. BJU Int (2006) 2.00
Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol (2010) 1.99
Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. Am J Surg Pathol (2004) 1.97
Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol (2004) 1.95
Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res (2006) 1.94
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol (2013) 1.92
Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. J Urol (2009) 1.91
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol (2002) 1.90
Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J Clin Oncol (2008) 1.89
Solid renal cortical tumors: differentiation with CT. Radiology (2007) 1.87
Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer (2002) 1.85
Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol (2008) 1.83
Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol (2002) 1.82
Renal vein or inferior vena caval extension in patients with renal cortical tumors: impact of tumor histology. J Urol (2004) 1.81
Contemporary imaging of patients with a renal mass: does size on computed tomography equal pathological size? BJU Int (2008) 1.79
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell (2016) 1.79
Contemporary use of partial nephrectomy at a tertiary care center in the United States. J Urol (2009) 1.78
Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol (2011) 1.76
Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. Eur Urol (2007) 1.76
Renal cortical tumors: use of multiphasic contrast-enhanced MR imaging to differentiate benign and malignant histologic subtypes. Radiology (2012) 1.75
Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study. Radiology (2012) 1.74
Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol (2010) 1.73
The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications. Eur Urol (2009) 1.70
Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol (2006) 1.69
Oncologic outcome after laparoscopic radical prostatectomy: 10 years of experience. Eur Urol (2008) 1.66
Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study. Am J Surg Pathol (2011) 1.64
SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res (2010) 1.64
Trends in renal tumor surgery delivery within the United States. Cancer (2010) 1.62
Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res (2005) 1.61
Routine drain placement after partial nephrectomy is not always necessary. J Urol (2011) 1.61